ASCO Releases First Living Guidelines for Metastatic Castration-Resistant Prostate Cancer

The American Society of Clinical Oncology (ASCO) has issued its first continuously updated guidelines on systemic therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). These new guidelines, informed by recent clinical trials, emphasize the importance of genetic testing and the earlier use of radiotherapeutics in treatment strategies.